Thesis

Pliant Therapeutics trades at 45 cents on the dollar versus its liquid assets. Market cap $87M, cash $192M, enterprise value negative $105M. The market is pricing PLN-101095 — the company's surviving oncology program — at negative money.

The market is wrong about the probability of total loss. Not necessarily wrong about the drug — that's unknowable from n=10 — but wrong about the weight it assigns to the bear case. The market implies 61% probability of bear outcome. Our analysis, after competitive landscape corroboration and safety signal contextualization, puts it at 30%. That 31-point gap is where the alpha lives.

This is a mispricing thesis, not a prediction thesis. We're not calling the biology. We're saying the market over-applies the bexotegrast failure heuristic to a mechanistically distinct program, ignores the competitive vacuum in αvβ8, and underweights the best-in-class efficacy signal in ICI resistance.

The Setup

What happened: Lead program bexotegrast (αvβ6/αvβ1 inhibitor for IPF) was terminated March 2025 after a DSMB recommendation due to adverse event imbalance. Stock cratered 80%+. Market wrote off the entire company.

What survived: PLN-101095, an oral small molecule dual αvβ8/αvβ1 integrin inhibitor combined with pembrolizumab for secondary ICI-refractory solid tumors. Phase 1 data shows:

• 40% ORR in secondary ICI-refractory patients (4/10 evaluable)
• 1 confirmed complete response, 2 confirmed partial responses
• Median time on treatment 15 months — durable
• IFN-γ biomarker: 4-13x increases in ALL responders, zero in non-responders
• Well tolerated: only 2/16 discontinuations for adverse events

For context, 40% ORR in secondary ICI-refractory solid tumors is best-in-class. The competition: visugromab 14-18%, mRNA-4359 24%, solnerstotug 14%, ICI rechallenge 19.4%. Only MDNA11 (42%, also small N) is comparable. The unmet need is massive — 61% of ICI patients develop acquired resistance with no approved targeted therapy.

What the balance sheet shows: $192.4M in cash and short-term investments. Zero long-term debt (Oxford loan paid off October 2025). Two restructurings complete (49 employees from ≈100+). Forward burn estimated $50-70M in 2026 versus $128M in 2025. Three-year runway minimum.

The Bull Case

Competitive vacuum is real. Both Pfizer (PF-06940434) and Corbus (CRB-601) discontinued their αvβ8 programs in 2025 — neither showed efficacy as monotherapy mAbs. Scholar Rock shelved SRK-181 (TGFβ1, oncology). PLRX is the only surviving clinical-stage αvβ8 program showing anti-tumor activity.

The key distinction: competitors used monoclonal antibodies targeting αvβ8 alone. PLN-101095 is an oral small molecule dual inhibitor used in combination with pembrolizumab. Different modality, different mechanism of engagement, and — evidently — different results.

Bexotegrast safety signal is likely disease-specific. The BEACON-IPF AE imbalance was driven by IPF progression events (worsening disease, acute exacerbation, respiratory hospitalization) with an unusually low placebo event rate (<3% versus standard ≈10%), not elevated treatment toxicity. Bexotegrast targets αvβ6/αvβ1 — different primary integrin than PLN-101095's αvβ8/αvβ1. Supporting evidence: CRB-601 (αvβ8 mAb) showed no safety signal in 25 patients. Bexotegrast itself was safe in PSC (different disease context). PLN-101095 uses 14-day monotherapy dosing versus 33+ weeks where bexotegrast problems emerged.

The market sees "integrin drug failed → all integrin drugs risky." The mechanistic reality is more nuanced. That heuristic gap is mispriced.

AACR catalyst in 5 weeks. Phase 1 data accepted for oral presentation at AACR Clinical Trials Minisymposium, April 17-22, 2026. This is a premium slot — AACR doesn't give minisymposium orals to unremarkable data. First time PLN-101095 data will be presented to a broad KOL audience.

Phase 1b already initiated. Three cohorts: NSCLC, clear cell RCC, high TMB tumors. First enrollment anticipated Q2 2026. Interim data expected 2027. Management is committing capital — burned boats, not hedge language.

Poison pill renewed March 3, 2026. Board extended the stockholder rights agreement through March 2027. At negative EV, this is either defending against a lowball or positioning for a negotiated deal. Either way, the board is aware of the setup.

The Bear Case

n=10 is n=10. Four responders out of ten evaluable patients. Oncology Phase 1 signals fail to replicate roughly 60% of the time. The IFN-γ biomarker stratification is mechanistically clean and adds confidence beyond raw ORR, but this is still a tiny sample. Phase 1b interim data in 2027 is the resolution event.

Insiders are selling, not buying. CEO sold 89K shares ($114K), CFO 24K shares ($31K), COO 7K shares ($9K) — all on January 20, 2026, at ≈$1.28. Likely 10b5-1 plan execution given same-day timing and small dollar amounts. But they're selling at 41 cents on the dollar versus cash. Nobody on the inside is reaching into their pocket.

One-program dependency. If PLN-101095 fails — safety signal or efficacy miss — the company has nothing. Bexotegrast already demonstrated management's capacity for catastrophic program loss.

Lease overhang. 100,904 sqft for 49 employees. $38.3M total future payments, $5.6M annual cash drain. Management is "evaluating sublease opportunities" — that's hope, not a deal.

$150M ATM shelf undrawn. Not used yet, and the dilution math at $1.41 is catastrophic (selling $10M would dilute 11.5%). But the shelf exists. If burn surprises to the upside, management has a loaded gun pointed at shareholders.

Analyst consensus is polarized. Piper Sandler Overweight at $3. JP Morgan Underweight at $0. HC Wainwright Neutral at $0. Two analysts literally have zero-dollar targets.

Factor Decomposition

Statistical regression (250 days): 79.4% idiosyncratic variance, 21.6% XBI sector, negligible market/momentum. Clears the 75% idio threshold — this is a stock-specific story, not a biotech sector trade.

Six thesis factors, by variance contribution:

Our edge is concentrated in competitive context and behavioral mispricing — knowing PLRX is the only αvβ8 standing, knowing 40% ORR is best-in-class, knowing the safety signal is likely disease-specific. We do NOT have edge in predicting biological outcomes from n=10.

Edge-weighted variance: ≈30%. Below the 45-60% comfort zone for full-size positions. This sizes to 0.5-1.5% — lottery ticket with positive expected value.

Forward EV

Our probability-weighted scenarios (18 months):

Market-implied probabilities (reverse-engineering $1.41 from our targets): ≈0% bull, ≈39% base, ≈61% bear. The market assigns zero probability to the bull case and nearly 2x our bear probability.

Reward/risk at $1.41: 5.4:1. Upside EV $1.14/share versus downside EV $0.21/share.

Annualized edge-adjusted α: 14.6% (raw 59% × 30% edge%).

The options market confirms the catalyst structure. April expiry (spans AACR) shows P/C ratio 0.21 with $2 strike calls dominating at 3,596 OI — smart money positioned for upside. July expiry flips to P/C 3.74 with heavy $1 put buying (1,169 OI) — post-AACR protection. Translation: the market sees AACR as a pop-then-fade event. This is being traded as a catalyst, not a conviction hold.

Entry

Preferred approach: scaled entry before AACR.

• Tier 1: $1.35-1.41 (current) — 0.3% position
• Tier 2: $1.20-1.30 (50-day MA pullback) — 0.3% position
• Tier 3: Post-AACR if new patient data confirms — 0.4% position
• Stop: $0.90 (below 52-week low, thesis-breaking)
• Maximum position: 1.0%

The stock is +21% in the last month with RSI at 69.8 — near overbought. Volume spiked to 5.7x the one-week average. Something is stirring but the near-term entry is technically stretched. A pullback to the 50-day MA ($1.25) would be a cleaner entry.

The question that determines near-term direction: does AACR present new patient data beyond the original 10, or rehash December 2025 results? New responses from dose expansion → gap higher. Restatement → sell-the-news. We assign 30% probability to new data. Check the AACR abstract when published (≈2 weeks pre-meeting).

What We're Watching

Bullish triggers: New patient responses at AACR. Insider buying before April. Sublease announcement on Oyster Point. Breakthrough therapy designation application. Partnership interest.

Bearish triggers: AACR rehash with no new patients. Phase 1b enrollment delays. ATM shelf draw at current prices. Any PLN-101095 safety signal.

Resolution timeline: AACR April 17-22 is the visibility catalyst. Phase 1b interim data in 2027 is the resolution event. The thesis lives or dies on whether n=10 becomes n=40 with similar results.

Conclusion

PLRX is a post-disaster biotech trading at negative enterprise value with a surviving clinical program that shows best-in-class efficacy in a massive unmet need, a competitive vacuum where every competitor has quit, and a near-term catalyst in 5 weeks. The market's 61% bear probability is too high given the mechanistic distinction from bexotegrast, the competitive landscape, and the 3-year cash runway.

This is not a high-conviction call on the drug. It's a probability arbitrage on a market that has collapsed all integrin programs into "failed" when the surviving one uses a different target, different modality, and shows different results. Size small — 0.5-1.0% — because n=10 is genuinely uncertain. But the expected value is positive and the reward/risk is 5.4:1. At negative enterprise value, the market is paying you to take the bet.

Evidence